San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Ocunexus Therapeutics is raising $9,125,807.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, David Pool played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ocunexus Therapeutics

Targeting the nlrp3 inflammasome in autoinflammatory disease using novel therapeutics to modulate the dysregulated connexin43 hemichannel. OcuNexus has potential treatments for multiple front- and back-of-the-eye diseases and disorders, and is developing unique, patented therapeutics to treat ophthalmic diseases with high unmet needs that offer the potential to alter the standard of care. Based upon multiple pre-clinical studies, the company’s technologies are expected to be transferable to other acute and chronic disease indications in which the inflammasome has been implicated.

To learn more about Ocunexus Therapeutics, visit http://ocunexus.com/

Contact:
David Pool, Chief Financial Officer
858-677-0474
https://www.linkedin.com/in/david-pool-26929462/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved